Bevacizumab Controls Macular Oedema Related to Diabetes, Cataract Surgery
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Bevacizumab Controls Macular Oedema Related to Diabetes, Cataract Surgery

SAN FRANCISCO -- July 31, 2009 -- This month’s journal of Ophthalmology reports on use of bevacizumab to benefit patients with diabetes who have macular oedema as well as people who develop cystoid macular oedema after cataract surgery.

The Pan-American Collaborative Retina Study Group, led by J. Fernando Arevalo, MD, Caracas Central Ophthalmologic Clinic, Caracas, Venezuela, conducted a study of intravitreal bevacizumab in 139 eyes of 115 patients with diffuse macular oedema.

Within 1 month of injections, improvement could be detected. By the end of the 24 month follow-up period, vision had improved in 51.8% of eyes, and 97.1% of eyes were either stable or improved. No serious adverse effects occurred.

The Pan-American Collaborative Retina Study Group also reviewed the use of bevacizumab in patients with post-cataract surgery cystoid macular oedema who had not responded to standard treatment.

Usually the condition resolves without treatment and causes no permanent vision loss, but in a small percentage of patients vision remains worse than 20/40 and treatment is needed.

The researchers reviewed the records of 31 patients (36 eyes) who were treated with at least 1 intravitreal bevacizumab injection and followed for 12 months between 2005 and 2007.

At the study’s outset the mean best-corrected visual acuity was 20/200, and at 12 months the mean was 20/80. Most eyes (72.2%) improved and the rest remained stable (27.8%). Macular thickness also decreased in most eyes. Patients who received 2 or more injections were significantly more likely to improve. No adverse systemic or vision side effects or outcomes were reported.

“Large, randomized controlled clinical trials are needed to confirm intravitreal bevacizumab’s efficacy and safety in treating these conditions,” said Dr. Arevalo. “The results for diffuse macular oedema are very promising and suggest that combining anti-VEGF treatment with laser therapy may prove useful.”

SOURCE: American Academy of Ophthalmology

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities